Quarterly report pursuant to Section 13 or 15(d)

NON CONTROLLING INTEREST (Details)

v3.23.2
NON CONTROLLING INTEREST (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Net loss attributable to the non-controlling interest     $ (2,040) $ (2,307)
BioCorRx Pharmaceuticals, Inc [Member]        
Net loss $ (1,849) $ (7,257) $ (3,296) $ (9,533)
Average Non-controlling interest percentage of profit/losses 24.20% 24.20% 24.20% 24.20%
Net loss attributable to the non-controlling interest $ (448) $ (1,756) $ (798) $ (2,307)
Joseph DeSanto MD [Member]        
Net loss $ (1,881)   $ (3,550)  
Average Non-controlling interest percentage of profit/losses 35.00%   35.00%  
Net loss attributable to the non-controlling interest $ (658)   $ (1,242)